Of note, our finding of cognitive impairment and increased gliosis in such subjects is also significant because of the confirmed roles for these phenotypes in other major aging-biased disorders, such as neurodegenerative diseases
Its evidence base runs deep: in type-2 diabetes (SUSTAIN1) semaglutide cut HbA1c by 1.55 points[2], and in the 17,604-patient SELECT cardiovascular trial it reduced major cardiac events by 20% in adults with obesity and no diabetes[3]
For BPC-157 the proposed indication is ulcerative colitis, a callback to that abandoned Pliva program
MT-1 Melanotan I is a linear peptide that primarily binds with high affinity and selectivity to the Melanocortin 1 Receptor (MC1R)
On May 2, 2026, The Lancet published a randomized, double-blind, placebo-controlled trial (Klausen et al., Copenhagen University Hospital) testing once-weekly semaglutide 2.4 mg in 108 treatment-seeking adults with moderate to severe alcohol use disorder and comorbid obesity
